Institutional members access full text with Ovid®

Share this article on:

Perioperative β-blocker and statin therapy

Daumerie, Geraldine; Fleisher, Lee A

Current Opinion in Anesthesiology: February 2008 - Volume 21 - Issue 1 - p 60–65
doi: 10.1097/ACO.0b013e3282f35ea5
Cardiovascular anaesthesia: Edited by Stefan De Hert

Purpose of review Perioperative β-blockade and statin therapy have been advocated to reduce cardiac risk of noncardiac surgery. This review evaluates recent articles published on the cardioprotective effects of perioperative therapy with these medications.

Recent findings Initial studies evaluating β-blocker therapy during the perioperative period suggested that β-blockers may be beneficial in reducing cardiac deaths and myocardial infarctions. Later studies and recent meta-analyses, however, are less favorable and suggest that β-blockers may be associated with increased incidence of bradycardia and hypotension. One randomized trial and several cohort studies have found a significant reduction in cardiovascular complications with perioperative statin therapy. Additionally, statin withdrawal is associated with increased postoperative cardiac risk.

Summary Based upon the available evidence and guidelines, patients currently taking β-blockers should continue these agents. Patients undergoing vascular surgery who are at high cardiac risk should also take β-blockers. The question remains regarding the best protocol to initiate perioperative β-blockade. Statins should be continued in patients already taking these agents prior to surgery. The optimal duration and time of initiation of statin therapy remains unclear.

Department of Anesthesiology and Critical Care, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

Correspondence to Lee A. Fleisher, MD, University of Pennsylvania School of Medicine, 3400 Spruce Street Dulles 6, Philadelphia, PA 19104, USA Tel: +1 215 662 3738; fax: +1 215 349 5341; e-mail: fleishel@uphs.upenn.edu

© 2008 Lippincott Williams & Wilkins, Inc.